Only eight percent of CNS drugs will reach approval, in part because of the high adverse effects standards.
Pierre Geoffroy
Advertisement
Articles by Pierre Geoffroy
Advertisement
Latest Updated Articles
CNS Drug Liabilities in Early Phase Clinical TrialsPublished: May 1st 2013 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Challenges of Buying Blind: Why Providing the Clinical Outcome Assessment Measure Prior to License Execution Would Significantly Benefit Clinical Trial Set-Up
2
Moving Beyond Historical Site Data to Real-Time Patient Insight
3
How Community Sites Can Stay Competitive Under Growing Efficiency Pressures
4
Clinical Trials in 2026: Platformization, AI Fluency, and the Redrawing of the Value Chain
5